1. Home
  2. NEXT vs MESO Comparison

NEXT vs MESO Comparison

Compare NEXT & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NextDecade Corporation

NEXT

NextDecade Corporation

HOLD

Current Price

$7.66

Market Cap

2.0B

Sector

Energy

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$18.18

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEXT
MESO
Founded
2010
2004
Country
United States
Australia
Employees
N/A
81
Industry
Oil & Gas Production
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.8B
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
NEXT
MESO
Price
$7.66
$18.18
Analyst Decision
Hold
Strong Buy
Analyst Count
2
1
Target Price
$8.00
N/A
AVG Volume (30 Days)
2.8M
220.4K
Earning Date
05-01-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$629.74
Revenue Next Year
N/A
$30.65
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.75
$11.87
52 Week High
$12.12
$21.50

Technical Indicators

Market Signals
Indicator
NEXT
MESO
Relative Strength Index (RSI) 46.63 75.11
Support Level $6.93 $17.90
Resistance Level $8.83 $18.89
Average True Range (ATR) 0.36 0.47
MACD 0.06 0.40
Stochastic Oscillator 46.61 97.35

Price Performance

Historical Comparison
NEXT
MESO

About NEXT NextDecade Corporation

NextDecade Corp is a Houston-based energy company engaged in construction and development activities related to the liquefaction of natural gas, the sale of LNG, and the capture and storage of CO2 emissions. The group is constructing and developing a natural gas liquefaction and export facility located in the Rio Grande Valley near Brownsville, Texas (the Rio Grande LNG Facility). It also engaged in NEXT Carbon Solutions, advancing proprietary processes to lower the cost of utilizing carbon capture and storage (CCS) and help companies reduce their emissions and achieve their clean energy goals.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: